Reinforcing properties of fencamfamine: involvement of dopamine and opioid receptors.
Fencamfamine (FCF) is a psychostimulant classified as an indirect dopamine agonist. The conditioning place preference (CPP) paradigm was used to investigate the reinforcing properties of FCF. After initial preferences had been determined, animals were conditioned with FCF (1.75, 3.5, or 7.0 mg/kg; IP). Only at the dose of 3.5 mg/kg FCF produced a significant place preference. Pretreatment with SCH23390 (0.05 mg/kg; SC) or naloxone (1.0 mg/kg; SC) 10 min before FCF (3.5 mg/kg, IP) blocked both FCF-induced hyperactivity and CPP. Pretreatment with metoclopramide (10.0 mg/kg; IP) or pimozide (1.0 mg/kg, IP), respectively, 30 min or 4 h before FCF (3.5 mg/kg; IP), which blocked the FCF-induced locomotor activity, failed to influence place conditioning produced by FCF. In conclusion, the present study suggests that dopamine D1 and opioid receptors are related to FCF reinforcing effect, while dopamine D2 subtype receptor was ineffective in modifying FCF-induced CPP.
Planeta
C da S
Cda S
Departamento de Principios Ativos Naturais e Toxicologia, Faculdade de Ciências Farmacêuticas, UNESP, Araraquara, Brazil.
Aizenstein
M L
ML
DeLucia
R
R
D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D001667:Binding, Competitive / Q000187:drug effects; D000697:Central Nervous System Stimulants / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D003216:Conditioning, Operant / Q000187:drug effects; D065127:Dopamine D2 Receptor Antagonists; D008787:Metoclopramide / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology; D009636:Norbornanes / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D010868:Pimozide / Q000494:pharmacology; D051381:Rats; D017447:Receptors, Dopamine D1 / Q000819:agonists / Q000037:antagonists & inhibitors*; D017448:Receptors, Dopamine D2 / Q000819:agonists; D017450:Receptors, Opioid, mu / Q000819:agonists / Q000037:antagonists & inhibitors*; D012054:Reinforcement, Psychology
D001552:Benzazepines; D000697:Central Nervous System Stimulants; D065127:Dopamine D2 Receptor Antagonists; D009636:Norbornanes; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D017450:Receptors, Opioid, mu; D010868:Pimozide; D009270:Naloxone; D008787:Metoclopramide; C020900:fencamfamine